Atezolizumab plus bevacizumab produced similar outcomes as lenvatinib in patients with previously untreated HCC who were 80 years of age or older. Atezolizumab plus bevacizumab produced similar outcomes as lenvatinib in patients with previously untreated HCC who were 80 years of age or older.